CANTON, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the following upcoming investor conferences:
The Cantor Fitzgerald Global Healthcare Conference at the New York Marriott Marquis in New York, NY
The Morgan Stanley Global Healthcare Conference at the Sheraton Times Square in New York, NY
Webcasts of the fireside chat sessions will be accessible by visiting the “News & Events” section on the “Investor Relations” page of Organogenesis’s website www.organogenesis.com. Archives of the webcasts will be available for replay following the conference for approximately 30 days.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com
| Last Trade: | US$5.00 |
| Daily Change: | 0.04 0.81 |
| Daily Volume: | 398,860 |
| Market Cap: | US$634.300M |
August 07, 2025 February 27, 2025 November 22, 2024 November 12, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
